Healthcare organizations spent much of the past year wondering what healthcare reform might look like under a new Administration. Although uncertainty remains, one thing is clear: healthcare is increasingly becoming data-driven in its nature, transactional in its design, real-time in its speed and ultimately consumer-centric in its focus.
The fact that the Medicare Access and CHIP Reauthorization Act’s (MACRA) Quality Payment Program (QPP) and the two pathways within—the Merit-Based Incentive Payment System (MIPS) and Advanced Alternative Payment Models (Advanced APMs)—are complex comes as no surprise. The entirety of managing and improving patient outcomes while maintaining cost efficiencies is no small feat. Providers’ understanding of and readiness to operate within QPP requirements is paramount to successful implementation of value-based care.
The final rule for the second year of the Medicare Access and CHIP Reauthorization Act (MACRA)’s Quality Payment Program (QPP) takes important steps toward acknowledging the challenges and concerns voiced by stakeholders regarding the ability of some clinicians to meet QPP reporting requirements.
On November 2, 2017, the Centers for Medicare & Medicaid Services (CMS) released its 2018 final rule, reflecting updates and changes to the Medicare Access and CHIP Reauthorization Act’s (MACRA) Quality Payment Program (QPP).
Escalating drug costs are compelling many states to develop and implement policy solutions to stem its rise. In fact, earlier this year, New York became the first state to place a cap on drug spending growth in its Medicaid program. Drug costs are also putting pressure on private health plans, which are looking to outcomes-based contracts as a possible solution, according to a survey by Avalere.